Research Analysts Offer Predictions for Exelixis Q2 Earnings

Key Points

• Zacks Research raised its Q2 2026 EPS estimate for Exelixis to $0.75 from $0.72, while maintaining a Hold rating on the biotech stock. The broader consensus full-year earnings estimate is $3.15 per share.
• Exelixis beat expectations in its latest quarter, reporting $0.87 EPS versus the $0.75 consensus and revenue of $610.81 million, up 10% year over year. The company also posted strong profitability metrics, including a 35.08% net margin.
• Analyst sentiment remains mixed but generally cautious, with MarketBeat data showing a consensus Hold rating and average target price of $47.35, even as some firms lifted their price targets and one upgraded the stock to Strong Buy. The shares recently traded near $50, close to their 52-week high of $51.63.

Exelixis, Inc. (NASDAQ:EXEL - Free Report) - Equities research analysts at Zacks Research boosted their Q2 2026 EPS estimates for Exelixis in a report issued on Monday, May 25th. Zacks Research analyst Team now forecasts that the biotechnology company will post earnings of $0.75 per share for the quarter, up from their previous forecast of $0.72. Zacks Research has a "Hold" rating on the stock. The consensus estimate for Exelixis' current full-year earnings is $3.15 per share.

A number of other analysts have also weighed in on the stock. Wall Street Zen upgraded shares of Exelixis from a "buy" rating to a "strong-buy" rating in a report on Saturday, May 9th. Stifel Nicolaus increased their target price on shares of Exelixis from $44.00 to $47.00 and gave the stock a "hold" rating in a report on Wednesday, May 6th. Morgan Stanley increased their target price on shares of Exelixis from $49.00 to $50.00 and gave the stock an "equal weight" rating in a report on Wednesday, May 6th. Royal Bank Of Canada dropped their target price on shares of Exelixis from $46.00 to $43.00 and set a "sector perform" rating for the company in a report on Monday, March 2nd. Finally, HC Wainwright increased their target price on shares of Exelixis from $54.00 to $56.00 and gave the stock a "buy" rating in a report on Thursday, May 7th. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, eleven have given a Hold rating and two have given a Sell rating to the company's stock. Based on data from MarketBeat, Exelixis has a consensus rating of "Hold" and a consensus target price of $47.35.

Exelixis Stock Up 0.1%

Exelixis stock opened at $50.03 on Thursday. The company has a market capitalization of $12.58 billion, a PE ratio of 16.62, a P/E/G ratio of 1.06 and a beta of 0.38. The firm has a fifty day simple moving average of $45.64 and a two-hundred day simple moving average of $44.10. Exelixis has a twelve month low of $33.76 and a twelve month high of $51.63.

Exelixis (NASDAQ:EXEL - Get Free Report) last posted its quarterly earnings results on Tuesday, May 5th. The biotechnology company reported $0.87 earnings per share for the quarter, topping the consensus estimate of $0.75 by $0.12. The business had revenue of $610.81 million during the quarter, compared to the consensus estimate of $607.51 million. Exelixis had a net margin of 35.08% and a return on equity of 39.89%. The firm's revenue for the quarter was up 10.0% on a year-over-year basis. During the same period in the previous year, the firm posted $0.55 earnings per share.

Hedge Funds Weigh In On Exelixis

Several hedge funds and other institutional investors have recently modified their holdings of EXEL. Anchor Investment Management LLC increased its position in shares of Exelixis by 500.0% during the third quarter. Anchor Investment Management LLC now owns 600 shares of the biotechnology company's stock valued at $25,000 after buying an additional 500 shares during the period. Motiv8 Investments LLC purchased a new position in shares of Exelixis during the fourth quarter valued at about $26,000. Cassaday & Co Wealth Management LLC purchased a new position in shares of Exelixis during the first quarter valued at about $27,000. Root Financial Partners LLC purchased a new position in shares of Exelixis during the third quarter valued at about $28,000. Finally, Western Wealth Management LLC purchased a new position in shares of Exelixis during the first quarter valued at about $29,000. Hedge funds and other institutional investors own 85.27% of the company's stock.

Insider Activity at Exelixis

In related news, CFO Christopher J. Senner sold 34,901 shares of the business's stock in a transaction dated Monday, May 18th. The shares were sold at an average price of $50.00, for a total transaction of $1,745,050.00. Following the transaction, the chief financial officer owned 952,317 shares in the company, valued at $47,615,850. The trade was a 3.54% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director George Poste sold 60,000 shares of the business's stock in a transaction dated Thursday, May 7th. The shares were sold at an average price of $45.71, for a total transaction of $2,742,600.00. Following the transaction, the director owned 118,832 shares in the company, valued at $5,431,810.72. This represents a 33.55% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 161,982 shares of company stock valued at $7,742,501 over the last three months. Corporate insiders own 2.60% of the company's stock.

Exelixis Company Profile

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis's translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company's most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.